{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:59:15Z","timestamp":1785851955770,"version":"3.56.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A\/H5N1 influenza virus has significant pandemic potential, and vaccination is the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study evaluated the safety and immunogenicity of two MF59-adjuvanted, cell culture-derived H5N1 (aH5N1c) vaccine formulations in healthy pediatric subjects 6 months to 17 years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Subjects (N = 662) received 2 aH5N1c doses 3 weeks apart, containing either 7.5 \u03bcg (full dose) or 3.75 \u03bcg (half dose) hemagglutinin antigen per dose. Local reactions and adverse events (AEs) were assessed by age. Antibody responses were measured by hemagglutination inhibition assay and assessed as geometric mean titers, geometric mean ratios (GMRs) and percentages of subjects achieving titers \u22651:40 and seroconversion (NCT01776554).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>No vaccine-related serious AEs occurred. Incidence of solicited local reactions and systemic AEs were similar across vaccine groups. Tenderness and irritability in &lt;6-year olds, and injection site pain, myalgia and fatigue in 6\u201317-year olds were the most commonly reported reactions in both full- and half-dose recipients. Frequencies of AEs were lower after the second dose than the first dose in all vaccine and age groups. Three weeks after the administration of a second dose, both full- and half-dose formulations met the Center for Biologics Evaluation Research and Review (United States) and Committee for Medicinal Products for Human Use (EU) licensure criteria for titers \u22651:40 (full dose 96% subjects; half dose 86%), seroconversion (full dose 96% subjects; half dose 86%), and GMR (full dose GMR 262; half dose 84). Antibody responses were highest in 6\u201335-month olds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In pediatric subjects, both aH5N1c vaccine formulations were well tolerated and highly immunogenic, meeting both US and EU licensure criteria for pandemic influenza vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002345","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T18:06:52Z","timestamp":1557166012000},"page":"757-764","source":"Crossref","is-referenced-by-count":10,"title":["Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A\/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects"],"prefix":"10.1097","volume":"38","author":[{"given":"Pornthep","family":"Chanthavanich","sequence":"first","affiliation":[{"name":"Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Anderson","sequence":"additional","affiliation":[{"name":"Saint Louis University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phirangkul","family":"Kerdpanich","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bulitta","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, GmbH, Marburg, Germany (a GSK Company)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Kanesa-thasan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline LLC Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hohenboken","sequence":"additional","affiliation":[{"name":"Seqirus, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1542\/peds.2009-2628","article-title":"Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.","volume":"126","author":"Vesikari","year":"2010","journal-title":"Pediatrics"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1542\/peds.2008-2449","article-title":"Prevention of influenza: recommendations for influenza immunization of children, 2008\u20132009.","volume":"122","year":"2008","journal-title":"Pediatrics"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/cid\/cis295","article-title":"H5N1 avian influenza in children.","volume":"55","author":"Oner","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.vaccine.2004.08.044","article-title":"Population-wide benefits of routine vaccination of children against influenza.","volume":"23","author":"Weycker","year":"2005","journal-title":"Vaccine"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.1221466","article-title":"Influenza: options to improve pandemic preparation.","volume":"336","author":"Rappuoli","year":"2012","journal-title":"Science"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2012.05.013","article-title":"A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A\/H1N1 influenza vaccine in adult and elderly populations.","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase \u00bd clinical trial.","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/jit498","article-title":"Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.","volume":"209","author":"van der Velden","year":"2014","journal-title":"J Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","article-title":"Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.","volume":"31","author":"Vesikari","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6505a1","article-title":"Prevention and control of seasonal influenza with vaccines.","volume":"65","author":"Grohskopf","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59(\u00ae)-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/14760584.6.5.659","article-title":"MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.","volume":"6","author":"Puig Barber\u00e0","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1017919305501","article-title":"Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.","volume":"17","author":"Gasparini","year":"2001","journal-title":"Eur J Epidemiol"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2014.10.085","article-title":"Safety and immunogenicity of an MF59-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.","volume":"33","author":"Knuf","year":"2015","journal-title":"Vaccine"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS One"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4161\/hv.20248","article-title":"Homologous and heterologous antibody responses to a one-year booster dose of an MF59(\u00ae) adjuvanted A\/H5N1 pre-pandemic influenza vaccine in pediatric subjects.","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans.","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2012.03.053","article-title":"Assessment of the immunogenicity and safety of varying doses of an MF59\u00ae-adjuvanted cell culture-derived A\/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.","volume":"30","author":"Fukase","year":"2012","journal-title":"Vaccine"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201907000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:34:05Z","timestamp":1785850445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201907000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002345","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}